Who are long-course chemotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eloxatin, Platinum-based doublet chemotherapy, Mitomycin-C/ 5-Fluorouracil, TC, Mitoxantrone, Cytarabine, TC chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/long-course-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

long-course chemotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

long-course chemotherapy (long-course chemotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy. Area: Oncology.

phase 3 Chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

long-course chemotherapy (long-course chemotherapy) — Associazione Italiana per lo Studio del Pancreas. Long-course chemotherapy involves administering chemotherapy drugs over an extended period to target and kill cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
long-course chemotherapy TARGET	long-course chemotherapy	Associazione Italiana per lo Studio del Pancreas	phase 3	Chemotherapy
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
Platinum-based doublet chemotherapy	Platinum-based doublet chemotherapy	The First Hospital of Hebei Medical University	marketed	Platinum-based chemotherapy doublet	DNA (platinum-DNA adducts)
Mitomycin-C/ 5-Fluorouracil	Mitomycin-C/ 5-Fluorouracil	Medical University Innsbruck	marketed	Chemotherapy combination (alkylating agent + antimetabolite)
TC	TC	AGO Study Group	marketed	Chemotherapy combination regimen
Mitoxantrone, Cytarabine	Mitoxantrone, Cytarabine	The First Hospital of Jilin University	marketed	Chemotherapy combination (topoisomerase II inhibitor + nucleoside analog)	Topoisomerase II (mitoxantrone); DNA polymerase (cytarabine)
TC chemotherapy	TC chemotherapy	Agendia	marketed	Chemotherapy combination regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy class)

University Hospital, Rouen · 2 drugs in this class
Sun Yat-sen University · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
Beijing Biostar Pharmaceuticals Co., Ltd. · 1 drug in this class
Delcath Systems Inc. · 1 drug in this class
Ludwig-Maximilians - University of Munich · 1 drug in this class
Prof. Dr. med. Claus Rödel · 1 drug in this class
Prothena Biosciences Ltd. · 1 drug in this class
Seoul National University Hospital · 1 drug in this class
Shanghai Zhongshan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). long-course chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/long-course-chemotherapy. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing